【导读】 2025香港国际中医药大会在港启幕，以全球智慧共谋中医药高质量走向世 中国基金报记者 郭玟君 9月25日，由紫荆文化集团主办、紫荆杂志社承办的"2025香港国际中医药大会"在香港会议 展览中心盛大启幕。本次大会以"推动中医药高质量走向世界"为主题，汇聚来自中国内地及 港澳台地区、东南亚等"一带一路"沿线国家和地区的近500位专家学者、行业领袖及企业代 表，包括20余位院士、国医大师、岐黄学者，以及超过130家参展机构。大会通过稀有中药 材展览、中医药文化体验、中医药产品展销、名医讲座等多元形式，展现中医药的实用价值 与发展前景，吸引"政、产、学、研"各界代表参与，共商中医药国际化发展的新路径与新机 遇。 大会开幕式现场 大会以近半小时的港式"八段锦"暨太极养生六式功法、坐式养生功法作为开场。表演者将八 段锦、太极融入现代都市生活场景，为繁忙的"上班族"提供了简易的健身方式，现场观众反 应热烈，并纷纷跟学模仿，展现了中医文化在日常健康管理中的实用性。会场同步开设诸多 名企展区，展出多种珍贵中药材，配以图文解说，帮助参观者深入了解药材特性与临床应 用，为大家提供了广阔的交流平台。 全国政协副主席梁振英， ...

Core Points - On September 25, 2023, the company announced the issuance of a total of 400 million yuan in the first phase of ultra-short-term financing bonds for the year 2025 in the interbank bond market [2] Summary by Category Company Actions - The company has issued ultra-short-term financing bonds amounting to 400 million yuan [2] - The issuance is part of the company's financing strategy for the year 2025 [2] Market Context - The bonds were issued in the interbank bond market, indicating the company's engagement with broader financial markets [2] - This move may reflect the company's efforts to optimize its capital structure and manage liquidity [2]

Core Viewpoint - The company is committed to implementing the "1238" development strategy to strengthen and expand its core business in Ejiao, while also focusing on potential product expansion and nurturing external varieties [1] Group 1: Strategic Focus - The company aims to enhance its core Ejiao business and deepen its foundational operations [1] - There is a strategic emphasis on expanding potential products and nurturing external varieties [1] Group 2: Innovation and Digitalization - The company is advancing a systematic "one center, three high grounds + N joint" innovation system that integrates production, learning, and application [1] - The focus is on driving innovation and lean operations, enhancing digital capabilities around products and services [1] Group 3: Performance Goals - The company is dedicated to achieving stable and high-quality growth in its performance [1]

Core Viewpoint - The "Love in the Dog Days, Warm Winter" health-themed customer service festival organized by Kunlun Health Insurance aims to integrate health services with community support, enhancing the quality of life for residents through interactive health management experiences [1][3]. Group 1: Event Overview - The fourth edition of the health-themed customer service festival was successfully held in Hangzhou, focusing on the integration of "insurance + community" health services [1]. - The event featured a vibrant opening ceremony with performances from the community dance team, attended by local officials and community residents [1][2]. - The festival is part of Kunlun Health Insurance's annual brand activities, responding to the "Healthy China 2030" initiative, and has successfully attracted public participation since its inception in 2022 [3]. Group 2: Activities and Engagement - The festival included various interactive zones such as a health drink area, health equipment testing, DIY herbal sachets, and free health consultations, engaging numerous residents [4]. - The "Health Home" initiative in the Furong community has provided health monitoring services to nearly a thousand residents, averaging over 30 services per day, establishing itself as a model for community health services [4]. Group 3: Future Plans - Kunlun Health Insurance plans to continue using the "Health Home" as a hub for seasonal health activities, aiming to enrich the "insurance + service" ecosystem and support grassroots health prevention systems [5]. - The company is committed to making health services a tangible part of residents' daily lives, contributing to the "Healthy China" strategy [5].

Market Overview - The Chinese medicine sector experienced a decline of 0.36% on September 25, with Enwei Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers included: - Weikang Pharmaceutical, closing at 25.25 with a rise of 9.83% and a trading volume of 135,600 shares, totaling 329 million yuan [1] - Yisheng Pharmaceutical, closing at 7.98 with a rise of 1.53% and a trading volume of 80,000 shares, totaling 6.41 million yuan [1] - Major decliners included: - Enwei Pharmaceutical, closing at 32.25 with a drop of 3.09% and a trading volume of 8,950 shares, totaling 2.91 million yuan [2] - Zhendong Pharmaceutical, closing at 6.85 with a drop of 2.97% and a trading volume of 508,400 shares [2] Capital Flow - The Chinese medicine sector saw a net outflow of 462 million yuan from institutional investors, while retail investors contributed a net inflow of 315 million yuan [2] - The table of capital flow indicates that: - Wanbangde had a net inflow of 23.44 million yuan from institutional investors, but a net outflow of 29.29 million yuan from retail investors [3] - Jilin Aodong experienced a net inflow of 21.10 million yuan from institutional investors, with outflows from both retail and speculative investors [3]

Core Viewpoint - Dong-E E-Jiao reported a net profit attributable to shareholders of 818 million yuan in the first half of 2025, representing a year-on-year increase of 10.74% [1] - The company continues to implement mid-term dividends, distributing a cash dividend of 12.69 yuan per 10 shares, totaling approximately 817 million yuan, which accounts for 99.94% of the net profit for the first half of 2025 [1] Financial Performance - In Q2 2025, the company achieved a net profit of 393 million yuan, showing a year-on-year growth of 2.01% [1] - The net cash flow from operating activities for the first half of 2025 was 965 million yuan, indicating improvement compared to Q1 2025 [1] - The cash and cash equivalents at the end of the period stood at 4 billion yuan, reflecting a strong cash reserve [1] Business Strategy and Outlook - The company is focusing on "growth and breakthrough" themes to promote high-quality growth in 2025, with significant improvements in gross margin observed in recent years [1] - Continuous strengthening of online channel layout and ongoing expansion efforts are expected to support stable revenue growth [1] - The company maintains a "buy" rating based on its robust performance and cash flow improvements [1]

Group 1: Mechanical Equipment Industry - The report highlights the strong demand for both aviation engines and gas turbines, driven by the recovery of the aviation market and new power demands from AIDC, leading to a supply-demand imbalance in the industry [2][8] - Major players in the aviation engine market include GE, PW, and R&R, while gas turbine leaders are Mitsubishi Heavy Industries, Siemens Energy, and GE Vernova, indicating a competitive landscape dominated by foreign companies [2][11] - The backlog of orders for commercial aircraft remains historically high, with Boeing and Airbus having a combined backlog of 15,241 aircraft as of July 2025, which is expected to sustain high demand for the aviation engine sector [9] Group 2: Non-Banking Financial Sector - CITIC Financial Assets has shifted its focus to non-performing asset management and has disposed of most of its financial subsidiaries, allowing it to concentrate on core operations [4][13] - The company is actively investing in high-quality listed companies, holding stakes in major banks like Bank of China and CITIC Limited, which are expected to provide stable returns [4][15] - The report projects that the long-term equity investment strategy will effectively smooth out economic cycle fluctuations for CITIC Financial Assets [4][13] Group 3: Communication Industry - Runze Technology is positioned as a leading IDC provider with strong resource endowments and financing advantages through REITs, which are expected to drive high growth [5][16] - The company is set to benefit from the upward trend in IDC demand, particularly in first-tier cities and surrounding areas, as the industry shifts from cloud computing to AI-driven needs [5][16] - EBITDA projections for Runze Technology are expected to grow significantly from 3.689 billion yuan in 2025 to 6.388 billion yuan by 2027 [5][16] Group 4: Pharmaceutical and Biological Sector - Tianshili, a leading traditional Chinese medicine company, is expected to see EPS growth from 0.79 yuan in 2025 to 0.98 yuan by 2027, supported by strong R&D capabilities and a robust marketing system [6][21] - The company has accelerated its R&D pipeline under the influence of China Resources, with a focus on cardiovascular, neurological, and digestive products [6][20] - The report indicates that Tianshili's revenue for the first half of 2025 was 4.288 billion yuan, with a net profit of 775 million yuan, reflecting a stable performance despite market challenges [19][20]

Core Viewpoint - Qizheng Tibetan Medicine has experienced a decline in the number of shareholders for the second consecutive period, indicating potential shifts in investor sentiment and market dynamics [2] Shareholder Information - As of September 20, the number of shareholders for Qizheng Tibetan Medicine was 33,802, a decrease of 2,190 from the previous period (September 10), representing a decline of 6.08% [2] - This marks the second consecutive decline in the number of shareholders [2] Stock Performance - The closing price of Qizheng Tibetan Medicine on the reporting date was 26.48 yuan, reflecting an increase of 1.57%, although the stock has cumulatively decreased by 4.68% since the concentration of shares began [2] - The stock experienced one increase and eight decreases over the specific trading days [2] Financing and Margin Data - As of September 23, the latest margin trading balance for the stock was 178 million yuan, with the financing balance also at 178 million yuan [2] - Since the concentration of shares began, the financing balance has decreased by 31.9093 million yuan, a decline of 15.23% [2] Financial Performance - In the first half of the year, Qizheng Tibetan Medicine achieved operating revenue of 1.175 billion yuan, representing a year-on-year growth of 16.36% [2] - The net profit for the same period was 358 million yuan, reflecting a year-on-year increase of 10.04% [2] - The basic earnings per share were reported at 0.6756 yuan, with a weighted average return on equity of 8.58% [2]

Group 1 - The "Phoenix Bay Area Finance Forum 2025" was held in Guangzhou on September 23-24, focusing on the theme "New Pattern, New Path" and gathering global political, business, and academic elites to explore development opportunities [1] Group 2 - Wang Yonghui, Chairman of Guangzhou Xiangxue Pharmaceutical Co., Ltd., emphasized the spirit and aspirations of Chinese enterprises in the globalization process during his keynote speech [3] - He highlighted the explosive growth of Chinese biomedicine going abroad, with this year's overseas scale exceeding $80 billion, transitioning from simple product exports to intellectual property exports [3] - Wang pointed out that Traditional Chinese Medicine (TCM) represents unique Chinese cultural and medical resources, and it is currently facing a historic opportunity for internationalization [3] - He illustrated TCM's global influence, stating that "TCM is medicine for humanity, belonging to China and the world, as it is a shared wealth of all mankind" [3] - Despite its potential, he acknowledged that TCM's actual application in medicine remains limited, indicating that true acceptance and integration into global healthcare is still a distant goal [3]

Core Viewpoint - The company is committed to the inheritance and innovation of traditional Chinese medicine, actively advancing the research and development of innovative traditional Chinese medicine products and the secondary development of key varieties [1] Group 1: R&D Initiatives - The company is focusing on the modernization of classic formulas in the chronic disease field [1] - The company is exploring partnerships with research institutions in the classic formula area to promote project collaboration [1] Group 2: Strategic Partnerships - The company has established a strategic cooperation with Shantou University Medical College to jointly conduct new drug development and related basic and clinical research [1] - This partnership aims to accelerate the progress of innovative traditional Chinese medicine research and development [1]